MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

HA14-1

CAS No. : 65673-63-4

MCE 站：HA14-1

产品活性：HA14-1 是一种 Bcl-2/Bcl-x_L 拮抗剂。HA14-1 与 Bcl-2 上的特定口袋结合, IC₅₀ 约为 9 μM，并抑制 Bcl-2 功能。

研究领域：Apoptosis

作用靶点：Bcl-2 Family

In Vitro: HA14-1 is a nonpeptidic ligand of a Bcl-2 surface pocket. HA14-1 induces the activation of Apaf-1 and caspases, possibly by binding to Bcl-2 protein and inhibiting its function. The interaction of HA14-1 with the Bcl-2 surface pocket appeared to be specific for the chemical structure of HA14-1 as a series of synthetic analogs derived from HA14-1 containing various modifications are found to have widely different Bcl-2 binding activities. To examine the effect of HA14-1 on cell viability, HL-60 cells are treated with various concentrations of HA14-1 for 4 h. HA14-1 induces the death of HL-60 cells in a dose-dependent manner. At 50 μM, HA14-1 causes the lost of viability in more than 90% of the cells. HA14-1 is a Bcl-2/Bcl-xL antagonist.

In Vivo: Swiss nude mice are challenged with BeGBM cells (10⁴ injected s.c.). HA14-1 (400 nmol) in 100 μL free RPMI 1640-50% DMSO, or the carrier alone, is given at the site of injection once weekly from day 2 following cell injection. HA14-1 treatment does not have any significant effect on the growth of glioblastoma tumors in immunodeficient mice as monitored twice weekly by measuring the volume of the expanding tumors. Moreover, no gross organ toxicity or weight loss can be detected in mice receiving such treatment. To analyze whether HA14-1 treatment might enhance the efficiency of another antitumoral treatment, Swiss nude mice challenged with human glioblastoma multiforme cells are also given i.p. low doses of Etoposide (2.5 mg/kg in 200 μL of 0.9% NaCl 5 days a week from day 2 following cell injection) together with HA14-1 or mock treatment. Whereas Etoposide treatment is insufficient by itself to restrain the growth of glioblastoma cells, its combination with HA14-1 leads to a significant restrain on tumor growth as judged by the ability of the combined treatment to increase the doubling time of the tumor volume.

相关产品：Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Anti-Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Venetoclax  |  BT2  |  Chelerythrine chloride  |  Bax inhibitor peptide V5  |  A-1210477  |  BAI1  |  Dehydrocorydaline chloride  |  Gambogic Acid  |  Gossypol  |  BI-3812  |  Clitocine  |  PROTAC Bcl2 degrader-1  |  (R)-(-)-Gossypol acetic acid  |  MIM1  |  TW-37  |  (E)-Ferulic acid  |  Jaceosidin  |  Paris saponin VII  |  Bz 423  |  Dihydrokaempferol  |  MSN-125  |  TCPOBOP  |  BH3I-1  |  Thevetiaflavone  |  WEHI-539

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。